Comparing the current results to its competitors, Soligenix Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 1.19 %, recorded in the same quarter.
Soligenix Inc 's Comment on Competition and Industry Peers
The company competes with pharmaceutical and biotechnology firms with greater resources, as well as universities and research institutions such as the U.S. Army Medical Research Institute of Infectious Diseases. Its product HyBryte™ addresses cutaneous T-cell lymphoma (CTCL), a condition with no approved cure, while existing FDA-approved treatments target later stages. SGX302 operates in the psoriasis treatment market, which includes several FDA-approved topical and systemic therapies, including biologics and skin-directed treatments like Sorilux®, Dovonex®, and Cacitrene®. SGX94 (dusquetide) has no direct competitors due to its novel mechanism of action; however, emerging competition may come from companies focusing on antibiotic resistance, including Qu Biologics Inc., Innaxon Therapeutics, and Innate Pharma SA. In biodefense product development, competitors include public and private companies, universities, and government agencies such as the U.S. Army, which is developing the ricin vaccine candidate RVEc™. Additionally, companies like Panacea Biotec Ltd. are developing proprietary vaccines utilizing stabilization technology. Other competitors identified in company filings include SciClone and the U.S. Army Medical Research Institute of Infectious Diseases.
Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.
Longeveron Inc's business model involves the development and commercialization of regenerative medicine products using mesenchymal stem cells for various medical conditions.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
HCW Biologics Inc is a biotechnology company that operates on a business model focused on the research, development, and commercialization of biologic therapies. The company primarily focuses on developing and manufacturing novel biological products for various medical conditions. Their business model involves collaboration with industry partners, conducting clinical trials, and securing regulatory approvals for the commercialization of their biologic therapies.
Sources:
Soligenix inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Soligenix inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
